Case Study


7 pages
May 2006
Reference: IMD-1-0240

Venture Valuation conducts an independent valuation of Genedata, a Swiss start-up company in order to help Novartis Venture Fund analyze and structure the next financing round. Venture Valuation, under a tight investment timeframe, has to customize the evaluation process, using both quantitative and qualitative data, to meet the customers needs. The case outlines Genedata’s background, its product portfolio, competitive positioning, and issues that it will need to deal with in the near future. Learning Objective: This case is part of a three case series intended to draw the audience into the issues surrounding the valuation of a startup biotechnology company, one of the most speculative and volatile marketplace.

Biotechnology, Valuation, Start-up, Genomics, Software, Development Stage Enterprise, Pharmaceuticals
Field Research
© 2005
Available Languages
Related material
Teaching note
Case clearing houses
IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.

The Case Centre

Cranfield University

Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]

Harvard Business School Publishing

60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]

Asia Pacific Case Center

NUCB Business School

1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]


Research Information & Knowledge Hub for additional information on IMD publications

Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics